Good MorningEquity markets continue to tread water as investors and traders wait on the next FOMC policy statement. The FOMC is not expected to hike rates next week, but it will remain hawkish and may surprise the market with its rhetoric. The takeaway is that interest rates will most likely remain high for an indefinite amount of time, which will have a bearing on stocks. With rates on treasuries above the S&P 500 dividend average, they pose a headwind to equity prices.
The market may remain in a holding pattern for the summer. If the S&P 500 can not get above the 4,300 level next week, it will be the top of a trading range that could dominate price action for several years. In that scenario, investors must be vigilant and use market dips to build positions in high-quality stocks. Featured: Free Ticker: Anthropic's silent partner could soar after record $2 trillion IPO (Ad) 
|
Consumer Discretionary | |
Despite rising mortgage rates and a slightly cooling housing market, homebuilding stocks like Lennar (NYSE: LEN) and KB Homes (NYSE: KBH) are ripping higher and outperforming the S&P 500.
The sector was buoyed by positive earnings results from the likes of Redfin (NASDAQ: RDFN), Toll Brothers... Read the Full Story |
|
From Our Partners | | Marc Chaikin's system flagged Nvidia before it soared 864 percent, Super Micro before a 2,346 percent run, Vertiv before 611 percent, and AppLovin before 539 percent.
His latest model narrows an entire AI economy down to just five stocks - and Nvidia isn't one of them.
See the five companies his system is tracking next before Wall Street catches on. | | Watch the free presentation and see the five AI stocks now |
|
Consumer Discretionary | |
If you’ve been looking for a good time to get into Ollie’s Bargain Outlook (NASDAQ: OLLI), that time could be now. The stock is pulling back after a solid report that brings nothing but good news for investors. The takeaways include shifting trends and accelerating purchasing habits, i... Read the Full Story |
|
Consumer Staples | |
Campbell Soup Company (NYSE: CPB) fell more than 6.5% following its Q3 report for no good reason. The company’s results were better than expected, and the guidance was reaffirmed and might be considered cautious. The news was no catalyst for the rally but also not a spark to send investors r... Read the Full Story |
|
From Our Partners | | Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. Its valuation has doubled since the announcement, with some estimates putting the company's worth near 3 trillion dollars by IPO day.
Google, Amazon, Nvidia and Microsoft have all taken stakes, while Goldman Sachs, Morgan Stanley and JPMorgan are competing for private shares. Anthropic's annualized revenue reportedly grew 80 times in the first quarter alone.
See how investors are positioning ahead of this closely watched IPO. | | Learn how to get a stake before the Anthropic IPO |
|
Communication Services | |
The story of Netflix Inc.'s (NASDAQ: NFLX) turnaround potential is getting investors' attention. The streamer's stock is up 23.71% in the past month, gapping up on May 18 following news that it has almost 5 million users of its advertising-supported service, and more than a quarter of new signups ... Read the Full Story |
|
Technology | |
Over the last five weeks, MicroVision (NASDAQ: MVIS) stock is up almost 300%, marching in an almost straight line upwards, with only two red days since the rally started.
The stock has become the subject of a short squeeze; social media hype and the company's past involvements in augmented realit... Read the Full Story |
|
From Our Partners | | Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade.
This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan. | | Claim your free options guide and start building real trading knowledge |
|
Consumer Discretionary | |
If you are familiar with The Lovesac Company (NASDAQ: LOVE), you know many things to love about it. The furniture is attractive, comfortable, and high-quality, and its modular design is easy to use. You may also know that there are reasons to hate the stock. The brand came out of nowhere and took ... Read the Full Story |
|
Consumer Discretionary | |
Lightning struck for Thor Industries (NYSE: THO) when lockdowns and social distancing became the norm, and it has struck again for this RV industry leader. The Q3 results are not excellent because sales are down high-double-digits compared to last year, but, regarding normalization within the indu... Read the Full Story |
|
Consumer Discretionary | |
Dave & Busters Entertainment (NASDAQ: PLAY) has had a rebound brewing for years. The company has worked diligently to overcome pandemic-inspired woes to become more prominent, stronger, and more profitable, yet the stock price lags its peers by a wide margin. One reason may be the analysts who... Read the Full Story |
|
Technology | |
Unity Software (NYSE: U) saw its share price rocket higher Monday afternoon and closed the day up almost 20% after Apple (NASDAQ: AAPL) announced they are working together on the Apple Vision Pro headset.
The breaking news caused Unity’s stock to break above the declining 200 SMA, tear abov... Read the Full Story |
|
Technology | |
In today's market, it would seem that every stock and company with the word 'technology' entrenched in its business model is enjoying a significant rally this month; the new sentiment comes from the breakthroughs seen during NVIDIA's (NASDAQ: NVDA) last quarterly performance.
Shares of NVIDIA ros... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. | | View Today's Stock Pick |
|
